Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome

Clinical Chemistry

Volumn 52, Issue 10, 2006, Pages 1920-1925

  Cardona, Fernando ^b   Morcillo, Sonsoles ^b   Gonzalo Marín, Montserrat ^c   Garrido Sanchez, Lourdes ^b   Macias Gonzalez, Manuel ^b   Tinahones, Francisco J ^a,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Hospital University Carlos Haya de Málaga   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d c/o Manuel Vazquez Montalban no 1 ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AMINO ACID SEQUENCE; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POLYMERASE CHAIN REACTION; POSTPRANDIAL STATE; PPARG GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN E3; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTPRANDIAL PERIOD; PPAR GAMMA; VARIATION (GENETICS);

EID: 33749145610     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.069690     Document Type: Article

References (31)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002;4:494-500.
3. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397-403.
4. Antonucci T, Whitcomb R, McLain R, Lockwood D, Morris RM. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997;20:188-193.
5. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997;17:1756-64.
6. Yen C-J, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator-activated receptor g (hPPARg) gene in diabetic Caucasians: identification of a Pro12Ala PPARg 2 missense mutation. Biochem Biophys Res Commun 1997;241:270-74.
7. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-87.
8. Beamer BA, Yen CJ, Andersen BE, Muller D, Elahi D, Cheskin LJ, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma-2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806-8.
9. Ek J, Urhammer SA, Sørensen TI, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation activated receptor-gamma-2 (PPAR-g): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999;42:892-5.
10. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, et al. Effect of the Pro12Ala variant of the human peroxisome proliferator- activated receptor gamma-2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998;251:195-8.
11. Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor gamma-2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001;144: 277-82.
12. Vaccaro O, Mancini FP, Ruffa G, Sabatino L, Iovine C, Masulli M, et al. Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma-2 gene in healthy individuals. Clin Endocrinol (Oxf) 2002;57:481-6.
13. Cardona F, Morcillo S, Gonzalo-Marin M, Tinahones F. The apolipoprotein E genotype predicts postprandial hypertriglyceridemia in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2972-5.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Cardona F, Gonzalo-Marín M, Tinahones FJ. Relation of postprandial hypertriglyceridemia with insulin resistance in patients with the metabolic syndrome: postprandial hypertriglyceridemia and metabolic syndrome. Endocrinología Nutrición 2006;53:237-41.
16. Queipo-Ortuno MI, Garcia-Ordonez MA, Colmenero JD, Morata P. Hydrogen peroxide improves the efficiency of a peripheral blood PCR assay for diagnosis of human brucellosis. Biotechniques 1999;27:248-250.
17. Nieters A, Becker N, Linseisen J. Polymorphisms in candidate obesity genes and their interaction with dietary intake of n-6 polyunsaturated fatty acids affect obesity risk in a sub-sample of the EPIC-Heidelberg cohort. Eur J Nutr 2002;41:210-21.
18. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, et al. The PPARg2 amino acid polymorphism Pro12Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetología 1999;42:758-62.
19. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPARg2 may confer resistance to type 2 diabetes. Biochem Biophys Res Comm 2000;271:212-6.
20. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84: 3708-12.
21. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P. Impact of the peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-9.
22. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, et al. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 2001;50:886-90.
23. Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor gamma-2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001;144: 277-82.
24. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor gamma-2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178-82.
25. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-48.
26. Wilson DE, Emi M, Iverius PH, Hata A, Wu LL, Hillas E, et al. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J Clin Invest 1990;86:735-50.
27. Julien P, Vohl MC, Gaudet D, Gagne C, Levesque G, Despres JP, et al. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes 1997;46:2063-8.
28. Van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triacylglycerol and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005;28: 844-9.
29. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000;11:243-51.
30. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002;22:2607-19.
31. Peng DQ, Zhao SP, Nie S, Li J. Gene-gene interaction of PPARG and ApoE affects coronary heart disease risk. Int J Cardiol 2003;92:257-63.